z-logo
open-access-imgOpen Access
Sleep Apnea Syndrome: Prevalence and Comorbidity with Other Non-communicable Diseases and HIV Infection, among Hospitalized Patients in Yaoundé, Cameroon
Author(s) -
M. Massongo,
Leonard Ngarka,
Adamou Dodo Balkissou,
V. Poka-Mayap,
Steve Voufouo Sonwa,
Godwin Y. Tatah,
Leonard N. Nfor,
Michel K. Mengnjo,
Eric-Samuel Chokoke,
Ben Patrick Michel Moutlen,
Stephen Perrig,
E.W. Pefura-Yone,
Alfred K. Njamnshi
Publication year - 2022
Publication title -
sleep disorders
Language(s) - English
Resource type - Journals
eISSN - 2090-3545
pISSN - 2090-3553
DOI - 10.1155/2022/4359294
Subject(s) - medicine , comorbidity , pediatrics , sleep apnea , neurology , sleep medicine , obstructive sleep apnea , cross sectional study , sleep disorder , psychiatry , cognition , pathology
Background. Sleep apnea syndrome (SAS), a growing public health threat, is an emerging condition in sub-Saharan Africa (SSA). Related SSA studies have so far used an incomplete definition. This study is aimed at assessing SAS using an American Academy of Sleep Medicine (AASM) complete definition and at exploring its relationship with comorbidities, among patients hospitalized in a Cameroonian tertiary hospital. Methods. This cross-sectional study was conducted in cardiology, endocrinology, and neurology departments of the Yaoundé Central Hospital. Patients aged 21 and above were consecutively invited, and some of them were randomly selected to undergo a full night record using a portable sleep monitoring device, to diagnose sleep-disordered breathing (SDB). SAS was defined as an apnea − hypopnea   index   AHI ≥ 5 /h, associated with either excessive daytime sleepiness or at least 3 compatible symptoms. Moderate to severe SAS (MS-SAS) stood for an AHI ≥ 15 / h . We used chi-square or Fisher tests to compare SAS and non-SAS groups. Findings. One hundred and eleven patients presented a valid sleep monitoring report. Their mean   age ± standard   deviation (range) was 58 ± 12.5 (28–87) years, and 53.2% were female. The prevalence (95% confident interval (CI)) of SAS was 55.0 (45.7, 64.2)% and the one of MS-SAS 34.2 (25.4, 43.1)%. The obstructive pattern (90.2% of SAS and 86.8% of MS-SAS) was predominant. The prevalence of SAS among specific comorbidities ranged from 52.2% to 75.0%. Compared to SAS free patients, more SAS patients presented with hypertension (75.4% vs. 48.0%, p = 0.005 % ), history of stroke (36.7% vs. 32.0%, p = 0.756 ), cardiac failure (23.0% vs. 12.0%, p = 0.213 ), and combined cardiovascular comorbidity (80.3% vs. 52.0%, p = 0.003 ). Similar results were observed for MS-SAS. Metabolic and neuropsychiatric comorbidities did not differ between SAS and SAS-free patients. Conclusion. The SAS diagnosed using modified AASM definition showed high prevalence among patients hospitalized for acute medical conditions, as it was found with SDB. Unlike HIV infection, metabolic and brain conditions, cardiovascular comorbidities (hypertension and cardiac failure) were significantly more prevalent in SAS patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom